29 completed, 18 recruiting, 15 active not recruiting, 10 terminated. 90 Phase 2, 17 Phase 1, 3 Phase 3.
Follow dabrafenib: new trials by email Literature Review of dabrafenib trials Research Report on dabrafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 12 | 2026-12-31 | 2026-10-21 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer Ipilimumab N01, Sintilimab, Cetuximab - BRAF V600E, Colorectal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 49 | 2026-03-01 | 2026-04-07 |
| Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI) - BRAF V600 Mutation, Low-grade Glioma | Phase 2 | Recruiting | University of California, San Francisco | 96 | 2025-11-07 | 2026-10-26 |
| Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children Dabrafenib or Trametinib and Clofarabine - Langerhans Cell Histiocytosis (LCH) | Phase 2 | Recruiting | West China Second University Hospital | 20 | 2025-06-01 | 2025-06-15 |
| MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas Trametinib and Nivolumab, Dabrafenib, trametinib, nivolumab - Low Grade Glioma, High Grade Glioma | Phase 1 / Phase 2 | Recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 27 | 2025-04-01 | 2026-07-10 |
| Precision Cancer Therapy in Rare Cancers Imatinib, Trametinib, Dabrafenib - Rare Malignant Neoplasm | Phase 2 | Recruiting | Oslo University Hospital | 96 | 2025-03-20 | 2025-03-26 |
| A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy - Neoplasms | Phase 2 | Recruiting | Blokhin's Russian Cancer Research Center | 64 | 2025-03-01 | 2025-05-18 |
| Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma Dabrafenib and trametinib (combination) - Ameloblastoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 46 | 2025-03-01 | 2025-02-11 |
| Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion Olaparib tablet, Temozolomide capsule, Anlotinib - Solid Tumor, Precision Medicine | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 300 | 2024-11-01 | 2024-12-18 |
| Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy Dabrafenib + Trametinib - Anaplastic Thyroid Cancer | Phase 2 | Unknown | Saint Petersburg State University, Russia | 10 | 2024-03-25 | 2024-04-12 |
| Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations Dabrafenib + Trametinib, Capmatinib - NSCLC, BRAF V600 Mutation | Phase 2 | Not yet recruiting | Sun Yat-sen University | 40 | 2024-02-01 | 2023-10-10 |
| Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma Oral dabrafenib and trametinib - Craniopharyngioma | Phase 2 | Recruiting | Eva Marie Erfurth, MD, PhD | 25 | 2023-09-01 | 2024-02-14 |
| Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations Dabrafenib, Trametinib - Cancer | Phase 2 | Unknown | Se Jun Park | 30 | 2023-06-20 | 2023-11-30 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma Dabrafenib, Trametinib - Ameloblastoma, BRAF V600E Mutation Positive | Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 12 | 2023-01-01 | 2024-10-22 |
| NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) dabrafenib/trametinib - Anaplastic Thyroid Cancer | Phase 2 | Recruiting | Leiden University Medical Center | 20 | 2023-01-01 | 2023-10-12 |
| A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C) - Advanced Solid Tumor, Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Immuneering Corporation | 209 | 2022-10-31 | 2026-10-20 |
| A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) Dabrafenib 75 MG, Trametinib 2 MG - Thyroid Cancer | Phase 2 | Unknown | Olivia Newton-John Cancer Research Institute | 80 | 2022-07-14 | 2023-10-31 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2026-11-10 |
Showing 20 of 90. Sign in to see all of them.
Melanoma (40) · Neoplasms (15) · Thyroid Carcinoma, Anaplastic (8) · Thyroid Neoplasms (8) · Brain Neoplasms (7) · Glioma (7) · Colorectal Neoplasms (6) · Hematologic Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Multiple Myeloma (5) · Neoplasm Metastasis (5) · Ameloblastoma (3) · Histiocytosis, Langerhans-Cell (3) · Skin Neoplasms (3) · Thyroid Cancer, Papillary (3)
Novartis Pharmaceuticals (11) · National Cancer Institute (NCI) (8) · GlaxoSmithKline (5) · M.D. Anderson Cancer Center (5) · Memorial Sloan Kettering Cancer Center (3) · Universitair Ziekenhuis Brussel (3) · Cancer Research UK (2) · Massachusetts General Hospital (2) · Melanoma Institute Australia (2) · Oslo University Hospital (2) · Saint Petersburg State University, Russia (2) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) · The Netherlands Cancer Institute (2) · University of California, San Francisco (2) · Abramson Cancer Center at Penn Medicine (1)
United States (44) · Australia (12) · France (12) · Germany (10) · China (9) · Italy (9) · United Kingdom (8) · Belgium (7) · Canada (7) · Netherlands (7) · Spain (7) · Japan (5) · Norway (5) · Denmark (4) · Russia (4)
Rodabe N Amaria (2) · Ahmad Awada, PhD (1) · Alain Algazi, MD (1) · Alain P Algazi (1) · Alan L Ho, MD, PhD (1) · Alexander Colevas (1) · Andrew M Scott, MD, FRACP (1) · Anne Hansen Ree, Prof. MD PhD (1) · Antoni Ribas (1) · Arjun Sahgal (1) · Ashley Plant-Fox, MD (1) · Bart Neyns, MD PhD (1) · Bart Neyns, MD, PhD (1)
PMID 34331515, PMID 36884302, PMID 24408395, PMID 26446943, PMID 36648215, PMID 37219859, PMID 37934000, PMID 15049016, PMID 18623218, PMID 19731321, PMID 23255383, PMID 23589673, PMID 23645591, PMID 24983357, PMID 25092772, PMID 25287827, PMID 25797743, PMID 26194764, PMID 26340744, PMID 26392102, PMID 26586415, PMID 26811525, PMID 27080216, PMID 27124486, PMID 27223498, PMID 27283860, PMID 27864013, PMID 28268064, PMID 28592387, PMID 28919011, PMID 28991513, PMID 29072975, PMID 29263218, PMID 29361468, PMID 29880583, PMID 30121602, PMID 30661097, PMID 31085763, PMID 31171444, PMID 31171878, PMID 31171879, PMID 31506385, PMID 31513482, PMID 31811016, PMID 31864178, PMID 32106306, PMID 32208873, PMID 32463741, PMID 32534242, PMID 32818466
U10CA180820 (3), 2015 (2), 2016 (2), U10CA032102 (2), U10CA180888 (2), U24CA196172 (2), 2017 (1), 2019 (1), 2023 (1), P30CA016672 (1), U01CA062490 (1), U01CA132194 (1), U10CA180830 (1), U10CA180886 (1), UM1CA081457 (1)